Skip to content

Effect of increasing of insulin received pantoprazole in pregnant women with diabetes situation, blood glucose and glycosylated hemoglobin - a randomized clinical trial

Effect of increasing of insulin received pantoprazole in pregnant women with diabetes situation, blood glucose and glycosylated hemoglobin - a randomized clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201109274306N5
Enrollment
70
Registered
2015-02-09
Start date
2015-01-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes. Diabetes Mellitus

Interventions

Intervention 1: intervention group 40mg capsule pantoprazol (ramofarvins company)in one month and once a day befor breakfast. Intervention 2: in control group coreless capsule similar to pantoprazole
Treatment - Drugs
intervention group 40mg capsule pantoprazol (ramofarvins company)in one month and once a day befor breakfast.
in control group coreless capsule similar to pantoprazole filled with flour . Capsules Consumption for one month and one day before breakfast

Sponsors

Vice Chancellor for Research and Technology, Babol University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Diabetic women of 20-35 years of age who are treated with insulin and who are in their 28th week of pregnancy will enter the study. Exclusion criteria: currently receiving proton pump inhibitors (omeprazole, Pantoprazole); IUGR detected by ultrasound; liver failure ( levels of liver enzymes more than three times the normal range), renal disease (Cr>1.5mg/dL); any diabetes complications; drinking alcohol or taking narcotics; hemoglobinopathies; reticulocytosis; anemia; blood transfusion needed during the study; uremia and any condition requiring hospitalization of the pregnant women.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
HBA1C. Timepoint: Before and one month after pantoprazole tablet. Method of measurement: HB%.;C-peptide. Timepoint: Before and one month after pantoprazole tablet. Method of measurement: ng/ml.;FBS. Timepoint: Before and one month after pantoprazole tablet. Method of measurement: mg/dl.;Gastrin. Timepoint: Before and one month after pantoprazole tablet. Method of measurement: pmo/l.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNeda Mahdinezhad Gorji

Fatemeh Zahra Infertility Research Center

n.mahdinejad@yahoo.com+98 11 3227 4881

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026